Journal Of Cancer Research And Clinical Oncology SCIE

國際簡稱：J CANCER RES CLIN 參考譯名：癌癥研究與臨床腫瘤學(xué)雜志

主要研究方向：醫(yī)學(xué)-腫瘤學(xué) 非預(yù)警期刊審稿周期：約1.0個月

《癌癥研究與臨床腫瘤學(xué)雜志》(Journal Of Cancer Research And Clinical Oncology)是一本由Springer Berlin Heidelberg出版的以醫(yī)學(xué)-腫瘤學(xué)為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q3 JCR分區(qū)
969 年發(fā)文量
2.7 IF影響因子
未開放 是否OA
87 H-index
1904 創(chuàng)刊年份
Monthly 出版周期
English 出版語言

The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.

The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.

[ 查看全部 ]

投稿咨詢加急咨詢

Journal Of Cancer Research And Clinical Oncology期刊信息

ISSN：0171-5216
出版語言：English
是否OA：未開放
E-ISSN：1432-1335
出版地區(qū)：GERMANY
是否預(yù)警：否
出版商：Springer Berlin Heidelberg
出版周期：Monthly
創(chuàng)刊時間：1904
開源占比：0.366
Gold OA文章占比：35.02%
OA被引用占比：0.1835...
出版國人文章占比：0.24
出版撤稿占比：0
研究類文章占比：89.06%

Journal Of Cancer Research And Clinical Oncology CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

1.023

0.953

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q3	207 / 404	48%
大類：Medicine 小類：Cancer Research	Q3	154 / 230	33%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Journal Of Cancer Research And Clinical Oncology中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	3區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	3區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	3區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	ONCOLOGY 腫瘤學(xué)	3區(qū)

Journal Of Cancer Research And Clinical Oncology JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q3	163 / 322	49.5%

按JCI指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q3	172 / 322	46.74%

Journal Of Cancer Research And Clinical Oncology歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Journal Of Cancer Research And Clinical Oncology中國學(xué)者發(fā)文選摘

1、Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study
Author: Lin, Xinqing; Deng, Haiyi; Li, Suyang; Xie, Xiaohong; Chen, Chao; Cai, Longqiu; Yang, Yilin; Qiu, Guihuan; Xie, Zhanhong; Qin, Yinyin; Liu, Ming; Zhou, Chengzhi

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 757-764. DOI: 10.1007/s00432-021-03903-0
2、Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Author: Cao, Yanshuo; Lu, Ming; Sun, Yu; Gong, Jifang; Li, Jie; Lu, Zhihao; Li, Jian; Zhang, Xiaotian; Li, Yan; Peng, Zhi; Zhou, Jun; Wang, Xicheng; Shen, Lin

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 779-789. DOI: 10.1007/s00432-021-03898-8
3、Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
Author: Sun, Chao; Liu, Yunpeng; Zhang, Peng; Wang, Xu; Xu, Yinghui; Lin, Xingyu; Ma, Xiaobo; Guo, Ye; Qiu, Shi; Shao, Guoguang; Yang, Zhiguang; Ma, Kewei

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 819-831. DOI: 10.1007/s00432-021-03896-w
4、Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer
Author: Poon, Darren M. C.; Yang, Bin; Geng, Hui; Wong, Oi Lei; Chiu, Sin Ting; Cheung, Kin Yin; Yu, Siu Ki; Chiu, George; Yuan, Jing

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 841-850. DOI: 10.1007/s00432-022-03950-1
5、Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion
Author: Zhao, Yongfeng; Zhou, Fuling

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 995-1006. DOI: 10.1007/s00432-022-03948-9
6、The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
Author: Wu, Guowu; Guo, Longhua; Gu, Yinfang; Huang, Tanxiao; Liu, Ming; Zou, Xiaofang; Yang, Bo; Huang, Ping; Wen, Chunling; Yi, Lilan; Liao, Wenting; Zhao, Dongdong; Zhu, Junlin; Zhang, Xiaoni; Liu, Yuanyuan; Yin, Yan; Chen, Shifu

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1019-1028. DOI: 10.1007/s00432-022-03959-6
7、Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis
Author: Zhang, Shuwen; Chen, Jingjing; Zhang, Rui; Xu, Liqin; Wang, Yan; Yuan, Zaixin; Hou, Xiaohui; Feng, Jian

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1063-1077. DOI: 10.1007/s00432-022-03970-x
8、Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer
Author: Du, Wei; Chen, Chen; Lin-feng Luo; Li-na He; Wang, Yixing; Zhang, Xuanye; Zhou, Yixin; Lin, Zuan; Hong, Shaodong

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1103-1113. DOI: 10.1007/s00432-022-03978-3